172 related articles for article (PubMed ID: 21739203)
1. Prognostic significance of HER2/neu expression in gastric cancer.
Ananiev J; Gulubova M; Manolova I; Tchernev G
Wien Klin Wochenschr; 2011 Jul; 123(13-14):450-4. PubMed ID: 21739203
[TBL] [Abstract][Full Text] [Related]
2. Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers.
Ananiev J; Gulubova M; Tchernev G; Penkova M; Miteva R; Julianov A; Manolova I
Wien Klin Wochenschr; 2011 Nov; 123(21-22):668-73. PubMed ID: 22015652
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma].
Song Y; Huang J; Wang JW
Chin J Cancer; 2010 Jan; 29(1):76-81. PubMed ID: 20038314
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray.
Rakhshani N; Kalantari E; Bakhti H; Sohrabi MR; Mehrazma M
Asian Pac J Cancer Prev; 2014; 15(18):7597-602. PubMed ID: 25292034
[TBL] [Abstract][Full Text] [Related]
5. Immunoexpression of PTEN, HER2/neu, and Ki-67 in endoscopic gastric carcinoma biopsies; their correlation with histological subtypes and one-year survival.
Acharya S; Thakur B; Mittal R
Indian J Pathol Microbiol; 2022; 65(1):29-34. PubMed ID: 35074962
[TBL] [Abstract][Full Text] [Related]
6. [Molecular biology and immunohistochemical studies of Her2/neu oncogene in stomach cancer].
Jähne J; Urmacher C; Albino A; Meyer HJ; Pichlmayr R
Chirurg; 1994 Apr; 65(4):307-11. PubMed ID: 7912666
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
8. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
9. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
10. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.
Zhou F; Li N; Jiang W; Hua Z; Xia L; Wei Q; Wang L
World J Surg Oncol; 2012 Dec; 10():274. PubMed ID: 23249720
[TBL] [Abstract][Full Text] [Related]
11. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
12. The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer.
Aznab M; Maleksabet D; Khazaei S; Khazaei M; Rezaei M
Asian Pac J Cancer Prev; 2019 Jul; 20(7):1989-1994. PubMed ID: 31350955
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
14. Expression of HER2/neu does not correlate with survival in soft tissue sarcoma.
Sato T; Peiper M; Heinecke A; Zurakowski D; Eisenberger CF; Hosch S; Knoefel WT; Izbicki JR
Onkologie; 2003 Jun; 26(3):268-71. PubMed ID: 12845212
[TBL] [Abstract][Full Text] [Related]
15. Is Helicobacter Pylori associated with Her2/neu Overexpression in Gastric Cancer Patients who Underwent Curative Resection?
Yoo MW; Han HS; Kim SY; Cho YH; Lee HG; Kim JH; Bang HY; Lee KY; Yoon SY
Hepatogastroenterology; 2014 May; 61(131):858-62. PubMed ID: 26176087
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
17. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
[TBL] [Abstract][Full Text] [Related]
18. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer.
Otsu H; Oki E; Ikawa-Yoshida A; Kawano H; Ando K; Ida S; Kimura Y; Aishima S; Saeki H; Morita M; Kohnoe S; Oda Y; Maehara Y
Anticancer Res; 2015 Apr; 35(4):2441-6. PubMed ID: 25862912
[TBL] [Abstract][Full Text] [Related]
19. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.
Subasinghe D; Sivaganesh S; Samarsekera A; Kumarasinghe MP; Samarasekera DN; Lokuhetty MDS
Dig Dis Sci; 2017 Sep; 62(9):2498-2510. PubMed ID: 28612195
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.
Wang D; Zhu H; Ye Q; Wang C; Xu Y
Medicine (Baltimore); 2016 Feb; 95(8):e2803. PubMed ID: 26937910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
